Thyroid cancer is the most common endocrine cancer, affecting more people each year as detection rates continue to rise.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new research findings suggesting the potential of novel molecular ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that new data presented at the 2023 American Thyroid Association (ATA) Annual Meeting demonstrate the type ...

Landmark studies leverage Afirma GRID whole transcriptome-derived data to identify molecular classifiers and signatures differentiating thyroid cancer risk groups The first study describes the ...

Towards a standard of care: Comparing stenting and ligation in parotid duct management for oral cancer. Progressive locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer ...

Papillary thyroid cancer is more common than medullary thyroid cancer and tends to be easier to treat. However, both types of thyroid cancer have a good prognosis in the early stages. If the cancer ...

The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC), which attempts to standardize reporting and cytological criteria for fine-needle aspiration (FNA) of thyroid nodules and was first ...

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the publication of two studies demonstrating the Afirma GRID (Genomic Resource for Intelligent Discovery)research ...